# SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-ca-23-034-sbir-phase-iib-bridge-awards-to-accelerate-the/  
Official notice: https://www.grants.gov/search-results-detail/347687

> National Institutes of Health offered grants to small businesses. Applications closed on August 21, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-CA-23-034 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | August 21, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.394, 93.395 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This Funding Opportunity Announcement (NOFO) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this NOFO is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This NOFO is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.

## Questions people ask

### Is RFA-CA-23-034 still open?

No. It closed on August 21, 2023.

### Who can apply for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)?

Closed August 21, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-CA-23-034?

NIH RePORTER lists 4 projects funded under RFA-CA-23-034 in fiscal 2024 to 2026, at 4 institutions. The most were at Privo Technologies, LLC, Doseoptics, LLC, Leuko Labs, Inc.

### Who has won Cancer Detection and Diagnosis Research grants before?

The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.